Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.
Acne fulminans is a syndrome of sudden onset hemorrhagic and ulcerative acne involving the back, chest, and face combined with systemic symptoms. It can be the dermatologic manifestation of the synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome. Current therapy for acne fulminans consists of wound care, topical and systemic corticosteroids, isotretinoin, and nonsteroidal anti-inflammatory drugs (NSAIDs). Infliximab, a recently developed monoclonal antibody against tumor necrosis factor-alfa, has shown efficacy in the treatment of psoriatic arthritis and ankylosing spondylitis both of which share clinical similarities to the SAPHO syndrome. We report the case of a patient with the SAPHO syndrome and acne fulminans who was treated with infliximab. Ten months after initiating therapy with infliximab, the area of the patient's ulcerative lesions was reduced by 70%. Infliximab might be considered as a treatment option for patients with acne fulminans unresponsive to conventional therapies.
Iqbal
Marvi
M
Department of Medicine, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance 90502, USA
Kolodney
Michael S
MS
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D020083:Acquired Hyperostosis Syndrome / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001706:Biopsy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D008159:Lumbar Vertebrae / Q000473:pathology; D008297:Male; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab